See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Natural Disasters
Trade War
Donald Trump
Social Media
Baseball
Stock Markets
Artificial Intelligence
Education
Soccer
Trade
Property
Published • loading... • Updated

Phase 3 trial of blood cancer treatment combo doses first patient

Summary by rarecancernews.com
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), a type of blood cancer. That’s according to an announcement from Innocare Pharma, the company developing both ICP-248 and orelabrutinib and sponsoring the trial. The Phase 3 study (NCT06378138) is being conducted at 50 sites in China. It is …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
rarecancernews.comrarecancernews.com

Phase 3 trial of blood cancer treatment combo doses first patient

The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), a type of blood cancer. That’s according to an announcement from Innocare Pharma, the company developing both ICP-248 and orelabrutinib and sponsoring the trial. The Phase 3 study (NCT06378138) is being conducted at 50 sites in China. It is …

Read Full Article
The AI JournalThe AI Journal

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelabrutinib as a first-line therapy for patients with chronic lymphocytic leukemia (CLL)/small ly…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The AI Journal broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cancer

Cancer

China

China

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal